Lifeboat Foundation

Researchers at Karolinska Institutet in Sweden have used DNA origami, the art of folding DNA into desired structures, to show how an important cell receptor can be activated in a previously unknown way. The result opens new avenues for understanding how the Notch signaling pathway works and how it is involved in several serious diseases. The study is published in Nature Communications.

Notch is a cell receptor that is of great importance to a wide range of organisms and plays a crucial role in many different processes, including early embryonic development in both flies and humans. Notch regulates the development of stem cells into different cell types in the body. Defects in this signaling pathway can result in serious diseases, including cancer.

The prevailing view of the receptor’s function has so far been that it is activated purely mechanically, by a neighboring cell pulling on it, meaning that signaling only occurs as a result of direct communication between cells.

Individuals with personality traits such as conscientiousness, extraversion, and positive affect are less likely to be diagnosed with dementia than those with neuroticism and negative affect, according to a new analysis by researchers at the University of California, Davis, and Northwestern University. The difference was not linked to physical damage to brain tissue found in dementia patients, but more likely to how certain personality traits help people navigate dementia-related impairments.

The work was recently published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Previous studies have tried to establish links between personality traits and dementia, but these were mostly small and represented only specific populations, said Emorie Beck, assistant professor of psychology at UC Davis and first author on the paper.

The Food and Drug Administration approved the use of Casgevy, a CRISPR gene-editing therapy, for treating the serious blood disorder transfusion-dependent beta thalassemia—the second major approval for the emerging therapy.

A.I. for longevity and long lived flies.

Kennedy Schaal presents “Using Advanced A.I. and Blockchain Technology to Targey Aging” at the Longevity+DeSci Summit NYC (EARD 2023) hosted by Lifespan.io. Summary ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ Kennedy Schaal is the founder and CEO of Rejuve Biotech, an AI-driven therapeutics discovery company solving the problems for longevity and age-associated diseases. By using advanced Artificial Intelligence to combine data from the Methuselah Flies with data from people, Rejuve. Bio can shorten the drug discovery pipeline and rapidly develop novel therapeutics to help people live longer. They have two high-impact and novel data sources, as well as unique artificial intelligence technology. First and foremost, they are the sole owner of data from the Methuselah Flies (fruit flies) that have been bred for longevity. Second, because flies have a shorter life cycle, they can be tested for longevity much faster than other animal models. Rejuve Biotech has the unique ability to test multiple interventions and treatment combinations over the course of a fruit fly’s life and in various aspects of its life (e.g., mating, disease resistance). In addition, they also have quick access to Crowdsourced Human Data collected by a partner company, Rejuve Network. Kennedy Schaal is an accomplished biotechnology executive with a strong leadership track record in applied genomic research and Artificial Intelligence at the frontier of longevity science. She is also a multi-published author on the science of longevity and applied genomics trials. Kennedy is also a world-leading expert on genomic selection and breeding for innovative Drosophila Methuselah Flies, which together with applied Artificial Intelligence solve many of today’s pain points in longevity research, with the potential for massive impact on the health and lifespan of people across the planet. Experienced Laboratory Director and Chief Biologist with a demonstrated history of working in the biotechnology industry. Strong research professional skilled in evolutionary biology, genetics, and the study of aging-related diseases.

Labroots recently explored how a November 2023 study published in The American Journal of Psychiatry found that cannabis does not mitigate long-term opioid addiction. Now, a more recent study published in The American Journal of Drug and Alcohol Abuse could either support or refute these findings as a team of international researchers examined the potential for cannabis to be used as appropriate substitute for weaning patients away from opioid use for non-medical reasons. This study holds the potential to help medical practitioners, patients, and the public better understand the link between medical cannabis and opioid addiction.

“Clarifying how cannabis and opioids interact is crucial if we are to equip healthcare professionals to provide evidence-based addiction treatment, prevent overdose deaths and save lives,” said Gabriel Costa, who is a researcher at the University of Ribeirão Preto in Brazil and lead author of the study.

For the study, the researchers combined findings from a meta-analysis and modeling to ascertain the risk of cannabis use and non-medical opioid use for patients suffering from opioid use disorder (OUD) and receiving appropriate treatment, as well. The meta-analysis involved a myriad of databases between March 1 and April 5, 2023, with a total of 10 studies being selected for further investigation for the final study, which totaled 8,367 participants, of which 62 percent were men and 38 percent were women.

AI becomes the decoder to predict treatment response.

Believe it or not, some types of cancers can grow resistant to chemotherapy.

Deciphering when cancer might toughen up against chemotherapy is pretty tricky. Even though researchers and doctors notice some hints and clues about resistance, predicting the exact moment is a bit like trying to hit a bullseye with a blindfold.

Continue reading “Scientists use AI to predict when cancer cells will resist chemotherapy” »

Factor in along w/ weird stories of secret labs in places like California.

GX_P2V had infected the lungs, bones, eyes, tracheas and brains of the dead mice, the last of which was severe enough to ultimately cause the death of the animals.

In the days before their deaths, the mice had quickly lost weight, exhibited a hunched posture, and moved extremely sluggishly.

Continue reading “Chinese lab crafts mutant COVID-19 strain with 100% kill rate in ‘humanized’ mice: ‘Surprisingly’ rapid death” »

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies—a human broadly neutralizing antibody and two antibodies isolated from previously vaccinated monkeys—target the fusion peptide, a site on an HIV surface protein that helps the virus fuse with and enter cells. The study, published in Science Translational Medicine, was led by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Antibodies that target the fusion peptide can neutralize diverse strains of HIV in vitro, that is, in a test tube or culture dish outside of a living organism. The NIAID VRC isolated a fusion peptide-directed human antibody, called VRC34.01, from a person living with HIV who donated blood samples for research. They also isolated two antibodies from rhesus macaques—a species of monkey with immune systems like humans’—who previously had received a vaccine regimen designed to generate fusion peptide-directed antibodies. Demonstrating that these antibodies protect animals would validate the fusion peptide as a target for human vaccine design. SHIV challenge—administering an infective dose of SHIV—to rhesus macaques is a widely used animal model for assessing the performance of HIV antibodies and vaccines.

In this study, rhesus macaques in each of four groups received a single intravenous infusion of one type of antibody—a 2.5 or 10 mg/kg of bodyweight dose of VRC34.01, or one of the two vaccine-elicited rhesus macaque antibodies—and other monkeys received a placebo infusion. To determine the protective effect of the antibodies, each monkey was challenged five days after infusion with a strain of SHIV known to be sensitive to fusion peptide-directed antibodies.

The PRISM AI system uses data from millions of patients to help identify those likely to develop the most common form of the disease.

A new AI system could help detect the most common form of pancreatic cancer, new research has found.